ImmuPharma (LON:IMM) – CORP: Update on Phase III study
Market Cap: £47m; Current Price: 38.8p
Rapid progress being made
ImmuPharma has provided an update on its Phase III clinical trial of Lupuzor™, which could lead to a potential breakthrough compound for Lupus – an auto-immune disease.
11 sites now active in the US.
5 European countries; Czech Republic, France, Germany, Hungry and Poland are recruiting Lupus patients and the UK and Italy are expected to open in the next few weeks.
In Mauritius over 10 patients have been pre-screened prior to dosing.
NORTHLAND CAPITAL PARTNERS VIEW: ImmuPharma is continuing to rapidly advance its Phase III clinical trials and is on track for its target to recruit 200 Lupus patients into the trail before the end of the year.
Premier African Minerals (LON:PREM) – CORP: Zulu update
Market Cap: £7m; Current Price: 0.38p
David Lenigas appointed as a consultant and drilling commences
A 20 hole (2,500m) diamond drilling has commenced at the Zulu lithium project, located in Zimbabwe. The programme is designed with the objective of establishing the depth and strike length of the mineralisation, as well as, establishing a complaint mineral resource estimate.
The bulk sample from Zulu has a Li2O content of 1.55%.
The Company has commenced a review of the strategic options for the development and monetisation of Zula and has appointed David Lenigas as a consultant to undertake this. The review will focus on the potential introduction of third-party strategic investors and joint venture partners, as well as, corporate or project level debt or equity investments.
Mr Lenigas will be paid £500 per month and be issued a warrant to subscribe for twenty-three million new ordinary shares at 0.8p.